JY
ELVN icon

Jeff Yass’s Enliven Therapeutics ELVN Stock Holding History

Jeff Yass’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.89M Buy
96,400
+28,300
+42% +$1.2M ﹤0.01% 4665
2026
Q1 		$2.67M Buy
+68,100
New +$1.89M ﹤0.01% 5521
2024
Q3 		– Sell
-8,700
Closed -$203K – 12213
2024
Q2 		$203K Buy
+8,700
New +$183K ﹤0.01% 10327
2023
Q4 		– Sell
-10,900
Closed -$149K – 12563
2023
Q3 		$149K Buy
+10,900
New +$184K ﹤0.01% 10549
2023
Q2 		– Sell
-179,500
Closed -$3.93M – 12314
2023
Q1 		$3.93M Buy
179,500
+136,100
+314% +$2.77M ﹤0.01% 3821
2022
Q4 		$710K Sell
43,400
-15,525
-26% -$248K ﹤0.01% 6986
2022
Q3 		$537K Buy
+58,925
New +$348K ﹤0.01% 8288

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Jeff Yass's ELVN Position: Q2 2026 in Review

Jeff Yass reduced its Enliven Therapeutics (ELVN) stake by 84% in Q2 2026, selling an estimated $899K and leaving 3,993 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #11923.

Jeff Yass first reported a position in ELVN in Q3 2021 and has held it in 11 quarters since. The position peaked at $1.12M in Q2 2025. 209 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Jeff Yass held 3,993 shares of Enliven Therapeutics worth $203K as of Q2 2026.
  • Jeff Yass sold 21,179 Enliven Therapeutics shares in Q2 2026, an estimated $899K.
  • Enliven Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11923 holding.
  • Jeff Yass first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • Jeff Yass's Enliven Therapeutics position peaked at $1.12M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.